Elephas Biosciences Partners With Neuberg Diagnostics in India

Aug 13, 2026
Elephas Biosciences has signed an exclusive commercial partnership with Neuberg Diagnostics to bring its elive immunotherapy response platform into India.

Elephas Biosciences has signed an exclusive commercial partnership in India with Neuberg Diagnostics, the companies announced in a press release.

Neuberg will become Elephas' commercial partner in India and bring the elive platform into its laboratory infrastructure. The companies plan for Neuberg to launch its own clinical test in India by the end of 2026.

Neuberg will also serve as Elephas' research partner in India. It will process tumor biopsy samples on the elive platform at its flagship laboratory in Ahmedabad to generate local evidence on the platform's performance.

Elephas says the elive platform assesses how live tumor tissue responds to oncology therapies. Neuberg is headquartered in Chennai and operates a network of more than 250 labs in India.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.